BMP Sunstone Sees Larger Market Share From China Healthcare Reforms, PE Buy Out In The Works?
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - U.S.-listed Chinese pharmaceutical manufacturer and distributor BMP Sunstone reported a 25.8 percent increase in revenue in the second quarter compared to the same year-ago period, for $40.9 million in revenue. The company anticipates gaining market share from China's ongoing healthcare reforms, for which the Chinese government has pledged to invest $124 billion from 2009 to 2011
You may also be interested in...
Sanofi Expands China Footprint In OTC And Rx Markets With BMP Sunstone Acquisition
Sanofi-Aventis has gained a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys
Sanofi Expands China Footprint In OTC And Rx Markets With BMP Sunstone Acquisition
Sanofi-Aventis has gained a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys
China's BMP Sunstone Reports Higher Profits With Launch Of National Healthcare Reforms
HONG KONG - U.S.-listed Chinese pharmaceutical manufacturer and distributor BMP Sunstone reported record profits in 2010